Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.85 |
| ▸ | MAPT | P10636 | 5/20 | 0.85 |
| ▸ | LMNA | P02545 | 3/20 | 0.85 |
| ▸ | HTT | P42858 | 2/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.85 |
| ▸ | RAB9A | P51151 | 5/20 | 0.83 |
| ▸ | NPC1 | O15118 | 4/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | CNR1 | P21554 | 7/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.71 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.71 |
| ▸ | RELA | Q04206 | 1/20 | 0.71 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.71 |
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | CA1 | P00915 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2682054 | 0.92 | KMT2A (1.00) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL29533340 | 0.91 | MEN1 (1.00) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL10344695 | 0.91 | MEN1 (1.00) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL24272428 | 0.89 | MEN1 (0.79) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL5852047 | 0.88 | MEN1 (0.77) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL11007034 | 0.88 | MEN1 (0.79) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL31206180 | 0.88 | MEN1 (0.77) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL29556162 | 0.87 | MEN1 (0.89) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL29077780 | 0.87 | MEN1 (0.89) | MEN1KMT2AMAPTLMNAHTT | |
| SCHEMBL1514631 | 0.86 | RAB9A (0.79) | MEN1KMT2AMAPTLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118436628-B | Application of diphenyl urea compound in preparation of toxoplasmosis-resistant medicament | 华南农业大学 | 2025-03-25 | — | — | CN | disclosed |
| CN-118436628-B | Application of diphenyl urea compound in preparation of toxoplasmosis-resistant medicament | 华南农业大学 | 2025-03-25 | — | — | CN | disclosed |
| US-20240409504-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY | 2024-12-12 | — | — | US | disclosed |
| US-20240317727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY | 2024-09-26 | — | — | US | disclosed |
| US-12098117-B2 | Compositions and methods for the treatment of cancer | DUKE UNIVERSITY (US) | 2024-09-24 | — | — | US | disclosed |
| CN-118436628-A | Application of diphenyl urea compound in preparation of toxoplasmosis-resistant medicament | 华南农业大学 | 2024-08-06 | — | — | CN | disclosed |
| CN-118436628-A | Application of diphenyl urea compound in preparation of toxoplasmosis-resistant medicament | 华南农业大学 | 2024-08-06 | — | — | CN | disclosed |
| US-20220106265-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY (US) | 2022-04-07 | — | — | US | disclosed |
| WO-2020123675-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY (US) | 2020-06-18 | — | — | WO | disclosed |
| US-4444863-A | UREA COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 1984-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409504-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | MEN1 4220/4885KMT2A 3139/4885MAPT 2167/4885 |
| US-12098117-B2 | Compositions and methods for the treatment of cancer | HSF1, HSP90AB1, HSP90AA1 | MEN1 4220/4885KMT2A 3139/4885MAPT 2167/4885 |
| US-20240317727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | MEN1 4220/4885KMT2A 3139/4885MAPT 2167/4885 |
| US-20220106265-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | MEN1 4220/4885KMT2A 3139/4885MAPT 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.